Insider Stock Trading History of Ray Debanjan


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Ray Debanjan since year 2005. The trader's CIK number is 1706863. At the time of this reporting, Ray Debanjan is the Chief Financial Officer of Cytomx Therapeutics, Inc. . (stock ticker symbol CTMX). See this page for all insider trading activities at Cytomx Therapeutics, Inc. .


Stock purchases, sales, and option exercises reported by insider Ray Debanjan since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2018-07-02 CTMX Cytomx Therapeutics, Inc. Option Ex 3,000 1.26 3,780
2018-07-02 CTMX Cytomx Therapeutics, Inc. Sale 3,000 22.56 67,680
2018-06-01 CTMX Cytomx Therapeutics, Inc. Sale 3,000 25.93 77,793
2018-06-01 CTMX Cytomx Therapeutics, Inc. Option Ex 3,000 1.26 3,780
2018-05-01 CTMX Cytomx Therapeutics, Inc. Sale 3,000 26.52 79,563
2018-05-01 CTMX Cytomx Therapeutics, Inc. Option Ex 3,000 1.26 3,780
2018-04-02 CTMX Cytomx Therapeutics, Inc. Option Ex 3,000 1.26 3,780
2018-04-02 CTMX Cytomx Therapeutics, Inc. Sale 3,000 28.12 84,360
2018-03-01 CTMX Cytomx Therapeutics, Inc. Option Ex 13,000 1.26 16,380
2018-03-02 CTMX Cytomx Therapeutics, Inc. Option Ex 20,000 1.20 23,940
2018-03-01 CTMX Cytomx Therapeutics, Inc. Sale 13,000 29.40 382,239
2018-03-02 CTMX Cytomx Therapeutics, Inc. Sale 20,000 30.50 609,900
2018-02-01 CTMX Cytomx Therapeutics, Inc. Sale 2,548 26.69 68,011
2018-01-02 CTMX Cytomx Therapeutics, Inc. Sale 2,500 21.11 52,775
2017-12-01 CTMX Cytomx Therapeutics, Inc. Sale 2,500 20.58 51,449
2017-11-01 CTMX Cytomx Therapeutics, Inc. Sale 2,500 20.00 50,000
2017-10-02 CTMX Cytomx Therapeutics, Inc. Sale 2,500 18.10 45,250
2017-09-01 CTMX Cytomx Therapeutics, Inc. Sale 2,500 17.17 42,925
2017-08-09 CTMX Cytomx Therapeutics, Inc. Sale 2,500 15.00 37,500
2017-07-03 CTMX Cytomx Therapeutics, Inc. Sale 2,500 15.47 38,675

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Ray Debanjan (Chief Financial Officer of Cytomx Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.